{"url":"https://lda.senate.gov/api/v1/filings/2f4e3a4d-2abb-43fe-bfba-d5287bcbe44e/","filing_uuid":"2f4e3a4d-2abb-43fe-bfba-d5287bcbe44e","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2023,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/2f4e3a4d-2abb-43fe-bfba-d5287bcbe44e/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"John McManus","dt_posted":"2023-04-20T17:39:35-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"610 10th St NW","registrant_address_2":"#300","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":286096,"url":"https://lda.senate.gov/api/v1/registrants/286096/","house_registrant_id":36969,"name":"THE MCMANUS GROUP","description":"Consulting","address_1":"610 10th St. NW","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JORDAN OPDAHL","contact_telephone":"+1 301-775-7048","dt_updated":"2026-07-20T15:27:02.288049-04:00"},"client":{"id":176479,"url":"https://lda.senate.gov/api/v1/clients/176479/","client_id":660,"name":"ALNYLAM PHARMACEUTICALS","general_description":"Biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-08-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies(DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable MedicalEquipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas;Extension of Timeline for Final Rule Publication (CMS-1687-RCN). Provisions included in Title I - Subtitle B of PL.117-169/H.R. 5376 - Inflation Reduction Act of 2022. Issues related to access and coverage in Medicare program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":9573,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MCMANUS","suffix":null,"suffix_display":null},"covered_position":"Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas","new":false},{"lobbyist":{"id":73075,"prefix":null,"prefix_display":null,"first_name":"ALANNA","nickname":null,"middle_name":null,"last_name":"TEMME","suffix":null,"suffix_display":null},"covered_position":"LD, Rep. Jon Porter","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}